For me, it's sobering to realize that another year passed while most primary care practices and hospitals around the world still lack a structural approach or resources to tackling #AMR.

Luckily the relentless energy of those AMR advocates offers an annual boost of morale

😱😱 it's not just the abstract

Thank you for sharing this. I don't get what @escmid.bsky.social hopes to obtain by restricting access after 6 months, or making it impossible to save posters

Vienna was marvelous and going from Copenhagen to ESCMID by day- and nightrain was a fantastic experience

I am surprised not to have picked up any major new treatment, prevention, or public health intervention breakthrough. I might have missed them, maybe I was queuing in the wrong lane, but blame the #ESCMIDGlobal app for that

8. A meeting organised by the ESCMID Study Group for Antimicrobial Stewardship actors involved in AMS in LMICs shared experiences. I retain that scaling of AMS beyond few tertiary care hospitals is nearly absent in LMIC, but still nowhere near in most HIC too. Let apart in primary care.

7. Two sessions on AMR and vaccines demonstrated again the lack of (recent) studies measuring effectiveness of (new+existing) vaccines on reducing antimicrobial use and AMR. Willian Hausdorff suggested developing combination vaccines by clinical presentation could better convince policy makers

6. Erika Vlieghe gave a talk on developing a sepsis national action plan in Belgium and had to start with a disclaimer on the complexity of healthcare decisionmaking, having to deal with 7 health ministers. Preventive and curative care are dealt with by different state levels.

5. Sonephet Vantava demonstrated how in hospitals in Lao PDR, healthcare worker attitudes and PPS antibiotic use data from will be combined to inform #AMS addressing frequent antibiotic use before and after delivery. Knowledge influences attitudes differently by profession @icarsglobal.bsky.social

Vilada Chansamouth then demonstrated how they used pathogen distribution and AMR prevalence data to develop guidelines in Lao PDR

4. A session on AMR surveillance gave excellent examples of analyzing and using clin micro AMR surveillance data, largely all examples from SE Asia. Many LMIC still struggle analyzing the data they have. Would be great if @WHO copy-pastes more from these examples

3. A session on biomarkers reviewed evidence on use of CRP to treat outpatient respi tract infections or fevers in low-resource settings. Large differences in effectiveness largely due to differences in antibiotic use prevalence. A cheap single malaria +semiquantitative CRP lateral flow test awaited

(I need to post one at a time apparently - takes a bit of time)

2. On relevant metrics to evaluate #AMS interventions: Days of Antibiotic Spectrum Coverage/DASC not only measures days of treatment but also at how wide the spectrum is of the antibiotic administered. Narrowing treatment is measured, and thus effectiveness in limiting selective pressure

1. Plans to harmonise and merge global-PPS and the WHO PPS. Countries I work with often pick the WHO PPS but then struggle to analyze antimicrobial use in sufficient detail to inform AMS or to benchmark w/ others. Planned for the next year or so, but still unclear how data sharing will go #ESCMID